摘要
目的分析甲磺酸阿帕替尼联合常规化疗治疗晚期非小细胞肺癌患者的疗效及不良反应。方法选取本院2018年4月至2019年3月收治的晚期非小细胞肺癌患者94例为研究对象,按随机数表法分为常规组和观察组,每组47例。常规组采用常规化疗,静脉输注紫杉醇+顺铂。观察组采用常规化疗联合甲磺酸阿帕替尼片。比较两组临床疗效及不良反应。结果观察组患者临床疗效优于常规组(P<0.05),且观察组患者血压上升、白细胞下降、血小板下降及蛋白尿等不良反应的总发生率显著低于常规组(P<0.05)。结论甲磺酸阿帕替尼联合常规化疗治疗晚期非小细胞肺癌患者疗效显著,能显著改善晚期非小细胞肺癌症状,且不良反应少,安全性高,可在临床推广使用。
Objective To analyze the efficacy and toxicity of apatinib mesylate combined with conventional chemotherapy in the treatment of advanced non-small cell lung cancer.Methods 94 patients with advanced non-small cell lung cancer admitted to our hospital from April 2018 to March 2019 were selected as study subjects.According to the random number table method,they were divided into routine group and observation group,with 47 cases in each group.The routine group received conventional chemotherapy and intravenous infusion of paclitaxel plus cisplatin.The observation group was treated with conventional chemotherapy combined with apatinib mesylate tablets.The efficacy and the adverse reactions were compared between two groups.Results The clinical efficacy of the observation group was better than that of the routine group(P<0.05),and the total incidence of adverse reactions such as blood pressure rise,leukocyte decrease,platelet decrease and proteinuria in the observation group was significantly lower than that in the routine group(P<0.05).Conclusion Apatinib mesylate combined with conventional chemotherapy in the treatment of advanced non-small cell lung cancer patients has a significant effect,can significantly improve the symptoms of advanced non-small cell lung cancer.At the same time,the drug has little side effects and high safety,and can be used in clinic.
作者
蒋轶
Jiang Yi(Department of The Second Oncology,Jiujiang NO.1 People's Hospital,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2020年第30期106-108,共3页
Contemporary Medicine
关键词
晚期非小细胞肺癌
甲磺酸阿帕替尼
疗效
不良反应
Advanced non-small cell lung cancer
Apatinib mesylate
Efficacy
Adverse reactions
